抗疟药依从性对新诊断系统性红斑狼疮患者死亡率的影响:基于人群的队列研究
该研究基于加拿大不列颠哥伦比亚省行政数据库,纳入1997年1月至2015年3月间新诊断SLE且新启用抗疟药(AM)的3062例患者,评估AM依从性与全因死亡的关系。中位随访6.4年期间242例(7.9%)死亡;与停药者相比,依从者死亡风险显著降低(边际结构Cox模型HRadj 0.17,95%CI 0.12-0.25),非依从者HRadj 0.58(95%CI 0.40-0.85),且死亡风险随依从水平呈显著趋势(P<0.001)。
要点
- 新诊断SLE患者坚持抗疟药治疗与全因死亡风险显著降低相关。
- 与停药者相比,依从者死亡风险降低约83%,非依从者降低约42%。
- 死亡风险随抗疟药依从水平提高呈显著下降趋势(P<0.001)。
核心结论
- 新诊断SLE患者中,坚持抗疟药治疗者较停药者死亡风险降低约83%,非依从者较停药者降低约42%。
研究设计与样本
- 基于加拿大不列颠哥伦比亚省行政数据库的人群基础队列研究,纳入1997年1月至2015年3月新诊断SLE且新启用抗疟药的3062例患者(平均年龄46.9岁)。
- 采用Cox模型和边际结构Cox模型(逆概率加权)评估抗疟药依从性(以30天窗口内覆盖天数比例PDC分类)与全因死亡的关系。
主要发现
- 平均随访6.4年期间,242例(7.9%)患者死亡。
- Cox模型调整后,与停药者相比,依从者(PDC≥0.90)死亡HRadj为0.20(95%CI 0.13-0.29),非依从者(0<PDC<0.90)为0.62(95%CI 0.42-0.91)。
- 边际结构Cox模型显示,依从者死亡HRadj为0.17(95%CI 0.12-0.25),非依从者为0.58(95%CI 0.40-0.85)。
- 死亡风险随依从水平变化呈显著趋势(P<0.001)。
关键数值与推荐
- 依从性定义:30天窗口内覆盖天数比例(PDC)≥0.90为依从,0<PDC<0.90为非依从,PDC=0为停药。
临床怎么用
- 在风湿免疫科管理中,应将抗疟药依从性作为SLE患者改善长期生存的关键可干预因素,定期评估并促进持续用药。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the association of antimalarial (AM) adherence with premature mortality among incident systemic lupus erythematosus (SLE) patients. METHODS: All patients with incident SLE and incident AM use in British Columbia, Canada, between January 1997 and March 2015 were identified using the provincial administrative databases. Follow-up started on the first day of having both SLE and AM. The outcome was all-cause mortality. An adherence measure, proportion of days covered (PDC), was calculated and categorized as adherent (PDC ≥ 0.90), nonadherent (0 < PDC < 0.90), and discontinuer (PDC = 0) during 30-day windows. We first used Cox models for time-to-death, adjusting for baseline and time-varying confounders on medication usages, health care utilization, and comorbidities. We then used marginal structural Cox models via inverse probability weighting designed for causal inference with time-varying confounders to assess the effect of AM adherence on premature mortality. RESULTS: We identified 3,062 individuals with incident SLE and incident AM use (mean age 46.9 years). Over the mean follow-up period of 6.4 years, 242 (7.9%) of those patients died. Adjusted hazard ratios (HRadj ) from the Cox model for AM adherent and nonadherent SLE patients were 0.20 (95% confidence interval [95% CI] 0.13-0.29) and 0.62 (95% CI 0.42-0.91), respectively, compared to discontinuers. The corresponding HRadj from the marginal structural Cox model were 0.17 (95% CI 0.12-0.25) and 0.58 (95% CI 0.40-0.85), respectively. A significant trend in the HRadj of mortality risk over the adherence levels was found (P < 0.001). CONCLUSION: Patients with SLE adhering to AM therapy had a 71% and 83% lower risk of death than patients who do not adhere or who discontinued AMs, respectively.
引用
- Hoque MR, Aviña-Zubieta JA, De Vera MA, et al. Impact of Antimalarial Adherence on Mortality Among Patients With Newly Diagnosed Systemic Lupus Erythematosus: A Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2022. PMID: 33411964. doi:10.1002/acr.24550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。